Maze Therapeutics develops small molecule drugs for kidney and metabolic diseases and has no approved products yet. It last closed at $31.37 on Nov 20, down 3.27% on the day. The next earnings report for MAZE is expected around Wed, Mar 24, 2027. For the quarter ended Sep 2026, MAZE reported EPS of -$0.79 on revenue of $0. Over its last 8 reports the stock moved an average of 6.5% the session after earnings. Over the last 12 months MAZE insiders bought $0 of stock on the open market and sold $25.0M, according to SEC Form 4 filings.
AI Auto Pilots
Is MAZE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MAZE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on MAZEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
MAZE · as of the Nov 20 close · updated each morning
Moving sideways
The stock sits between its 20 and 50 day averages. It is 1% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the 200 day average at $31.02, and the nearest resistance the Pivot at $31.68.
Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 6.3%/day
Key levels
$53.6552 week high+71.0%
$33.0020 day average+5.2%
$32.63Swing high (Oct 29)+4.0%
$32.49Pivot R1+3.6%
$31.68Pivot+1.0%
$31.37Last close
$31.02200 day average−1.1%
$30.57Pivot S1−2.6%
$29.75Swing low (Nov 2)−5.2%
$29.3950 day average−6.3%
$28.84100 day average−8.1%
$21.9552 week low−30.0%
Indicators
RSI (14)
47.47
Middle of its range
Neutral
MACD
0.85
Below its signal line
Bearish
Stochastic
23.6
Middle of its range
Neutral
ADX (14)
24.2
Weak trend
Williams %R
-83.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-60.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−8.3%
Change over 10 sessions
Bearish
ATR (14)
$1.98
Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNormal
VolatilityNormal, 12.7%/day
Key levels
$53.6552 week high+71.0%
$33.0020 day average+5.2%
$32.63Swing high (Oct 29)+4.0%
$32.49Pivot R1+3.6%
$31.68Pivot+1.0%
$31.37Last close
$31.02200 day average−1.1%
$30.57Pivot S1−2.6%
$29.75Swing low (Nov 2)−5.2%
$29.3950 day average−6.3%
$28.84100 day average−8.1%
$21.9552 week low−30.0%
Indicators
RSI (14)
54.26
Middle of its range
Neutral
MACD
0.62
Above its signal line
Bullish
Stochastic
78.3
Middle of its range
Neutral
ADX (14)
18.6
No clear trend
Williams %R
-39.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
123.9
Oversold below −100, overbought above 100
Overbought
Rate of change
+27.5%
Change over 10 sessions
Bullish
ATR (14)
$3.99
Typical daily range, 12.7% of price
MA 10Above
MA 20Above
MA 50Below
MA 100–
MA 200–
What happened before, for MAZE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MAZE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MAZEHow many large options trades hit MAZE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MAZE in the last 90 days.
From SEC Form 4 filings by MAZE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MAZE is in one of them and how their past MAZE trades turned out.
Maze Therapeutics is a biopharmaceutical company based in South San Francisco, California. It develops small molecule oral drugs for patients with kidney and metabolic diseases, using human genetic data to identify targets and guide development. Its most advanced candidate is in clinical trials for a genetically defined form of chronic kidney disease, and a second candidate is being prepared for trials in a metabolic disorder and chronic kidney disease. The company has no approved products, and it has partnered some of its programs with other drugmakers.